|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
66,620,000 |
Market
Cap: |
213.18(M) |
Last
Volume: |
14,666 |
Avg
Vol: |
14,625 |
52
Week Range: |
$3.05 - $7.84 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile MEI Pharma is a late-stage pharmaceutical company focused on the development and commercialization of cancer therapies to improve outcomes for patients. Co.'s portfolio of drug candidates includes three clinical-stage assets, including: Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor; Voruciclib, an oral cyclin-dependent kinase 9 inhibitor; and ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
336,100 |
417,600 |
Total Buy Value |
$0 |
$0 |
$2,112,595 |
$2,130,933 |
Total People Bought |
0 |
0 |
2 |
3 |
Total Buy Transactions |
0 |
0 |
6 |
7 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Rueckert William Dodge |
Director |
|
2008-11-20 |
4 |
B |
$0.50 |
$425 |
D/D |
849 |
20,849 |
2.31 |
- |
|
Rueckert William Dodge |
Director |
|
2008-11-18 |
4 |
B |
$0.84 |
$8,366 |
D/D |
10,000 |
20,000 |
2.39 |
- |
|
Novogen Ltd |
10% Owner |
|
2008-07-28 |
4 |
B |
$2.17 |
$6,311,000 |
D/D |
2,908,295 |
52,408,295 |
2.45 |
- |
|
Williams Bryan |
Director |
|
2008-03-13 |
4 |
B |
$2.52 |
$12,600 |
D/D |
5,000 |
5,000 |
2.39 |
- |
|
Seaton David R |
CFO & Secretary |
|
2008-03-13 |
4 |
B |
$2.20 |
$11,000 |
D/D |
5,000 |
5,000 |
2.74 |
- |
|
Rueckert William Dodge |
Director |
|
2008-03-08 |
4 |
B |
$2.25 |
$21,985 |
D/D |
9,771 |
1,000 |
2.39 |
- |
|
Rueckert William Dodge |
Director |
|
2008-03-07 |
4 |
B |
$2.20 |
$504 |
D/D |
229 |
229 |
2.31 |
- |
|
Naughton Christopher |
CEO & President |
|
2008-02-29 |
4 |
B |
$2.40 |
$8,640 |
I/I |
3,600 |
5,000 |
2.58 |
- |
|
Naughton Christopher |
CEO & President |
|
2008-02-27 |
4 |
B |
$2.40 |
$3,360 |
I/I |
1,400 |
1,400 |
2.58 |
- |
|
Rueckert William Dodge |
Director |
|
2007-12-21 |
4 |
S |
$2.50 |
$2,473 |
D/D |
(989) |
0 |
|
- |
|
Rueckert William Dodge |
Director |
|
2007-12-21 |
4 |
S |
$2.40 |
$26 |
D/D |
(11) |
989 |
|
- |
|
Rueckert William Dodge |
Director |
|
2007-03-27 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,000 |
|
- |
|
Novogen Ltd |
10% Owner |
|
2003-12-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
49,500,000 |
|
- |
|
113 Records found
|
|
Page 5 of 5 |
|
|